SCHEMBL107785

SCHEMBL107785

CCC(O)CCc1ccc(O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.52
ESR2 Q92731 2/20 0.52
SLC6A2 P23975 4/20 0.48
ADRA2A P08913 3/20 0.48
ADORA3 P0DMS8 3/20 0.48
SLC6A3 Q01959 3/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 3/20 0.48
TACR2 P21452 2/20 0.48
SLC6A4 P31645 2/20 0.48
ADRB3 P13945 2/20 0.48
LMNA P02545 2/20 0.48
CYP3A4 P08684 2/20 0.48
CHRM2 P08172 2/20 0.48
CHRM1 P11229 2/20 0.48
PTGS1 P23219 2/20 0.48
SHBG P04278 1/20 0.48
TP53 P04637 1/20 0.48
HSPD1 P10809 1/20 0.48
HTR2C P28335 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5950465 0.91 MMP12 (0.44) TRPV1ADRB2CA2HTR1A
SCHEMBL3653415 0.88 ESR1 (0.55) ESR1ESR2SLC6A2ADRA2AADORA3
SCHEMBL7270279 0.87 ESR1 (0.62) ESR1ESR2SLC6A2ADRA2AADORA3
SCHEMBL1934439 0.86 ESR1 (0.52) ESR1ESR2SLC6A2ADRA2AADORA3
SCHEMBL108916 0.83 CYP1A2 (0.45) DPP4TAAR1L3MBTL1TDP1CYP1A2
SCHEMBL27547657 0.83 TAAR1 (0.45) KDM4EPTGS1PTGS2TMEM97SIGMAR1
(+)-Hannokinol SCHEMBL23229864 0.83 ESR1 (0.56) ESR1ESR2SLC6A2ADRA2AALDH1A1
(+)-Hannokinol SCHEMBL30361499 0.83 ESR1 (0.56) ESR1ESR2SLC6A2ADRA2AALDH1A1
(+)-Hannokinol SCHEMBL31237222 0.83 ESR1 (0.56) ESR1ESR2SLC6A2ADRA2AALDH1A1
SCHEMBL5505572 0.82 STAT3 (0.41) ADRB3HSD17B10ADRB2ADRB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
EP-4098750-A1 RAPID PRETREATMENT Sweetwater Energy, Inc. (US) 2022-12-07 EP disclosed
EP-3230463-B1 RAPID PRETREATMENT SWEETWATER ENERGY INC (US) 2022-05-25 EP disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
US-5374629-A A triene steroids as anticarcinogenic agents, treating skin disorders LEO PHARMACEUTICAL PRODUCTS LTD. A/S LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB (DK) 1994-12-20 US disclosed
EP-0522013-B1 NOVEL VITAMIN D ANALOGUES LEO PHARM PROD LTD (DK) 1994-11-23 EP disclosed
EP-0522013-A1 NOVEL VITAMIN D ANALOGUES. LEO PHARM PROD LTD (DK) 1993-01-13 EP disclosed
WO-1991015475-A1 NOVEL VITAMIN D ANALOGUES Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) 1991-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA ESR1 3581/4885ESR2 3683/4885SLC6A2 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.